earn model updat
report earn morn revenue/ep
gener line consensu see chart full note jakafi
growth remain strong compani prepar
launch gvhd increment driver
revenu continu believ month
execut strategi diversif investor
start focu jakafi patent expiri
growth reiter
guidanc patient jakafi
mf although pv grow twice rate
extens rux pdufa steroid refractori acut
gvhd may compani prepar
launch us jakafi guidanc includ
contribut gvhd includ current off-
itacitinib acut steroid nave
studi also expect read-out
year nda
submiss pemigatinib cholangiocarinoma
nv capmatinib topic rux vitiligo result
addit updat baricitinib atop
derm well earlier stage read-out recent
outlook preview upcom catalyst
compani
model updat increas pt
updat earn slight increas outer year
revenu reflect potenti pipelin program
topic rux partnership
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
actual quarterli perform compar consensu
track guidanc detail past quarter
chang fair valu
guidanc
cash expect
epacadostat
here product level perform commentari prior quarter
yoy growth
yoy growth
yoy growth
growth pv
call
impact
end jakafi
inventori
mo
wind
pembro
fda approv mg
dose mg
adcom sale
sale
bari data
expect
medic
year
total patient
yoy total
mf
correct
combin
pim new moa
year adcom
ra
program
begin
roll commentari around pipelin last quarter
multipl jak combo underway mf
orr secondari durabl
look rr
multipl jak combo underway
mf itacitinib pim
mf itacitinib pim
mf itacitinib pim
snda accept prioriti
data expect
snda accept prioriti
review extend may
expect
atop dermat vitiligo
expect
expect
phase data melanoma expect
announc top-line failur echo-
analysi on-going
studi run variou
nsclc head neck run
convert phase
cancer trial convert
phase expans cohort
combin durvalumab
pivot lung trial initi
resubmiss complet decemb
approv mg dose us
proceed phase ad sle phase
releas medic meet
sle publish lancet
underway alopecia begin
sle atop dermat
alopecia begin
atop derm expect
initi sle
expect top-line
result studi
initi sle
psoriat arthriti prepar
citadel dlbcl meet
respons criteria studi
extend fl mzl mcl
phase dose escal
combin tagrisso
phase dose escal
combin tagrisso
phase gravita underway nave
acut gvhd combin steroid
phase gravita underway
nave acut gvhd combin
fl mzl mcl continu
fl mzl mcl continu
fl mzl mcl continu
phase dose escal
combin tagrisso
nave acut gvhd
combin steroid vs
phase dose escal
combin tagrisso
result expect
result expect
nda submiss expect
nda submiss expect
begin chronic gvhd
begin chronic gvhd
nda submiss expect
studi come month
nda submiss expect
recruit patient pivot
trial cholangiocarcinoma
program initi tumor-
high c-met data nsclc file
nv evalu data
nv evalu data
nv submit nda
nv submit nda
focu
focu
focu
select
focu
select
licens deal dose-
dose escal complet
focu combin
dose escal complet
focu combin
monotherapi on-going msi-
combin possibl
begin
initi preclin data oral
inhibitor
escal complet
focu combin
gitr clinic
inhibitor clinic develop
pt base dcf use discount rate appli commerci
stage biotech compani termin growth rate includ contribut jakafi et gvhd well
olumi also includ meaning gener catch-al line item captur program fgfr inhibitor
risk includ increas competit threat jakafi/olumi continu aggress develop spend jakafi
patent expiri approach next decad
articl articl
time dissemin februari
analyst josh schimmer shenston huang ami liu maneka mirchandaney primarili respons prepar research
report attest follow view opinion render research report reflect person view subject
compani issuer part research analyst compens directli relat specif
recommend view research report
